|
|
|
|
As genome editing advances clinically, mRNA delivery enables transient expression, scalable manufacturing, and supports next-generation editors and in vivo therapies.
|
|
|
|
|
Genome editing is rapidly expanding beyond CRISPR-Cas9, with new approaches enabling greater precision and therapeutic potential. Advances in delivery, manufacturing, and regulation will play a critical role in turning promising science into broadly accessible treatments.
|
|
|
|
|
Vector design is increasingly critical to gene editing success. Streamlined constructs can enhance efficiency, improve reproducibility, reduce development risks, and support smoother clinical translation and manufacturing.
|
|
|
|
|
Nanoplasmids are enabling advances across cell and gene therapy, from CRISPR HDR templates and transposon vectors to DNA vaccines and viral vector production. Discover the technology’s key advantages and real-world applications.
|
|
|
|
|
A research institute developing CRISPR-based genome editing needed a custom ultra-low endotoxin nuclease. See how expertise in Cas9 expression and purification supported neuron editing comparable to AAV9 delivery while reducing immune responses.
|
|
|
|
|
From process optimization to scalable manufacturing, successful mRNA production depends on maximizing yield and transcript integrity. Learn how to address common production challenges while supporting efficient development of mRNA and saRNA therapies.
|
|
|
|
|
